Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cara Therapeutics revenue
Cara Therapeutics's revenue is $7.1 million.
What is Cara Therapeutics's revenue?
- Cara Therapeutics's revenue growth from 2012 to 2024 is 499.75%.
- Cara Therapeutics has 84 employees, and the revenue per employee ratio is $84,964.
- Cara Therapeutics's peak quarterly revenue was $112.1M in 2020(q4).
- Cara Therapeutics peak revenue was $135.1M in 2020.
- Cara Therapeutics annual revenue for 2023 was 21.0M, -49.92% growth from 2022.
- Cara Therapeutics annual revenue for 2024 was 7.1M, -65.96% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Cara Therapeutics historical revenue
Cara Therapeutics's peak revenue was $135.1M in 2020. The peak quarterly revenue was $112.1M in 2020(q4).
Cara Therapeutics's revenue increased from $1.2m in 2012 to $7.1M currently. That's a 499.75% change in annual revenue.
Cara Therapeutics annual revenue
Cara Therapeutics annual revenue over time
| Fiscal year / year | Cara Therapeutics revenue |
|---|---|
| 2012 | $1.2M |
| 2013 | $12.0M |
| 2014 | $3.2M |
| 2015 | $3.8M |
| 2016 | $86,000 |
| 2017 | $911,000 |
| 2018 | $13.5M |
| 2019 | $19.9M |
| 2020 | $135.1M |
| 2021 | $23.0M |
| 2022 | $41.9M |
| 2023 | $21.0M |
| 2024 | $7.1M |
Rate Cara Therapeutics' financial transparency
Cara Therapeutics annual growth
Cara Therapeutics saw the greatest revenue growth in 2018, when revenue increased by 1,378.49%.
Cara Therapeutics had the lowest revenue growth in 2016, when revenue changed by -97.74%.
Cara Therapeutics annual growth rate over time
| Year | Cara Therapeutics growth |
|---|---|
| 2013 | 905%↑ |
| 2014 | -73%↓ |
| 2015 | 20%↑ |
| 2016 | -98%↓ |
| 2017 | 959%↑ |
| 2018 | 1378%↑ |
| 2019 | 48%↑ |
| 2020 | 579%↑ |
| 2021 | -83%↓ |
| 2022 | 82%↑ |
| 2023 | -50%↓ |
| 2024 | -66%↓ |
Cara Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Cara Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | - | $973,000 |
| 2014 | $178,000 | $960,000 | $1.1M | $914,000 |
| 2015 | $489,000 | $874,000 | $2.4M | - |
| 2016 | $7,000 | $79,000 | - | - |
| 2017 | $911,000 | - | - | - |
| 2018 | - | $2.9M | $5.1M | $5.5M |
| 2019 | $4.4M | $5.2M | $5.8M | $4.5M |
| 2020 | $8.1M | $5.6M | $9.3M | $112.1M |
| 2021 | $1.9M | - | $20.3M | $821,000 |
| 2022 | $4.8M | $23.0M | $10.8M | $3.3M |
| 2023 | $6.2M | $6.9M | $4.9M | $3.0M |
| 2024 | $2.1M | $991,000 | $2.6M | $1.5M |
Cara Therapeutics jobs nearby
Do you work at Cara Therapeutics?
Is Cara Therapeutics transparent about its revenue structure?
Cara Therapeutics financial information
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 84 |
| Date Founded | 2004 |
| Headquarters | Stamford, Connecticut |
| Number of Locations | 1 |
| Revenue | $7.1M |
| Net Income | -$85,474,000 |
| Gross Proft | $6.5M (2024) |
| PE Ratio | -9.43 |
| Tax Rate | 0.0% |
| Market Capitalization | $668.6M |
| Total Assets | $182,237,000 |
| Ticker | CARA |
Cara Therapeutics jobs you might like
Cara Therapeutics financing
Cara Therapeutics received early financing of $4.7M on 2005-12-21.
| Series | Round size | Date |
|---|---|---|
| Series B | $4.7M | 12/2005 |
| Series C | $24M | 11/2006 |
| Series C | $12.3M | 07/2008 |
| Series D | $15M | 07/2010 |
| Post Ipo Equity | $80.5M | 07/2015 |
| Post Ipo Equity | $92.1M | 03/2017 |
| Post Ipo Equity | $98.3M | 07/2018 |
| Post Ipo Equity | $145.5M | 07/2019 |
Cara Therapeutics investors
| Investors | Security type |
|---|---|
| Ascent Biomedical Ventures | Series B |
| Esperante BV | Series B |
| Ascent Biomedical Ventures | Series C |
| Scottish Widows Investment Partnership | Series C |
| Alta Partners | Series C |
| MVM PARTNERS LLP | Series C |
| Mitsubishi UFJ Capital | Series C |
| Ascent Biomedical Ventures | Series C |
| Connecticut Innovations | Series C |
| DEVON PARK BIOVENTURES | Series C |
| Mitsubishi Corporation | Series C |
| Ascent Biomedical Ventures | Series D |
| Scottish Widows Investment Partnership | Series D |
| Connecticut Innovations | Series D |
| DEVON PARK BIOVENTURES | Series D |
| Rho Ventures | Series D |
| Alta Partners | Series D |
| Mitsubishi Corporation | Series D |
| MVM PARTNERS LLP | Series D |
Cara Therapeutics competitors
Cara Therapeutics's top competitor, Ultragenyx Pharmaceutical, earned an annual revenue of $560.2M.
Cara Therapeutics's smallest competitor is Sollis Therapeutics with revenue of $130.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Bellerophon Therapeutics | - | $5.6M | 17 | - |
| Allakos | - | $15.6M | 125 | - |
| Aldeyra Therapeutics | - | $1.0M | 19 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Seres Therapeutics | - | $144.9M | 145 | - |
| Leap Therapeutics | - | $1.5M | 30 | - |
| Sollis Therapeutics | - | $130,000 | 7 | - |
| Centrexion Therapeutics | - | $790,000 | 29 | - |
| Acorda Therapeutics | - | $117.6M | 344 | - |
| Ultragenyx Pharmaceutical | - | $560.2M | 893 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Cara Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cara Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Cara Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cara Therapeutics. The data presented on this page does not represent the view of Cara Therapeutics and its employees or that of Zippia.
Cara Therapeutics may also be known as or be related to CARA THERAPEUTICS INC., CARA Therapeutics, Inc., Cara Therapeutics, Cara Therapeutics Inc and Cara Therapeutics, Inc.